Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)
Terminated · Phase 2 · NCT04888585
Conditions: Rheumatoid Arthritis (RA)
At a glance
- Research payments reported, 2025
- $39,280
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 473
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-154 (drug), Placebo (drug)
- Dates
- Started 2021-06-23; completion 2023-08-04
- Results posted
- Yes
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluated how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity were assessed. ABBV-154 is an investigational drug being evaluated for the treatment of RA. Study doctors placed the participants in 1 of 5 treatment groups or arms; each arm received a different treatment. There was a 1 in 5 chance that participants were assigned to placebo. Participants 18-75 years of age with moderate to severe RA were enrolled. Around 425 participants were to be enrolled in th…
From ClinicalTrials.gov, last updated 2024-10-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $39,280 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- George Karpouzas, M.D. Rheumatology · Torrance, CA
- Carlos A. Sesin, M.D. Rheumatology · Miami Beach, FL
- Jyothi R. Mallepalli, MD Rheumatology · Monroe, LA
- Alan Kivitz, MD Rheumatology · Duncansville, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sweet Hope Research Specialty Inc $25,001
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $10,278
- Altoona Center for Clinical Research $3,000
- Arthritis Clinic the $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.